[1] Simes EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2021 Dec 6;73(11):e4400-e4408. DOI:
10.1093/cid/ciaa951[2] Rodriguez-Fernandez R, et al. Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2021 May 1;40(5S):S35-S39. DOI:
10.1097/INF.0000000000003121